Eli Lilly’s Lepodisiran Study: A New Frontier in Liver Function Treatment

Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.

Study Overview: Eli Lilly and Company is conducting a Phase 1 study titled ‘A Phase 1, Multicenter, Sequential-Design, Single-Dose, Open-Label Study of Lepodisiran in Participants With Normal Hepatic Function and Participants With Mild, Moderate, or Severe Hepatic Impairment.’ The study aims to evaluate the pharmacokinetics and safety of lepodisiran, a drug administered via subcutaneous injection, in participants with varying degrees of liver function impairment compared to those with normal liver function.

Intervention/Treatment: The intervention being tested is lepodisiran, a drug administered subcutaneously. The study’s goal is to understand how the drug is absorbed and eliminated in the body and to assess its safety and tolerability in individuals with different liver function levels.

Study Design: This is an interventional study with a non-randomized, sequential design. It is open-label, meaning no masking is involved, and focuses on basic science. Participants are divided into groups based on liver function, receiving a single dose of lepodisiran.

Study Timeline: The study began on April 23, 2025, and the latest update was submitted on June 24, 2025. These dates are crucial as they indicate the study’s progression and current status, which is actively recruiting participants.

Market Implications: The study’s progress could influence Eli Lilly’s stock performance, as successful results may enhance investor confidence and market position. The pharmaceutical industry is competitive, and advancements in drug development for liver impairment can position Eli Lilly favorably against competitors.

The study is ongoing, with further details available on the ClinicalTrials portal.